Helen M. Thackray - Dec 19, 2022 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Role: Chief R&D Officer
Signature: /s/ Alane P. Barnes, by power of attorney
Stock symbol: BCRX
Transactions as of: Dec 19, 2022
Transactions value $: $0
Form type: 4
Date filed: 12/21/2022, 03:41 PM
Previous filing: Dec 19, 2022
Next filing: Apr 4, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BCRX	Common Stock	Award	$0	+81K	+60.78%	$0.00	214K	Dec 19, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BCRX	Emp. Stock Option (Right to Buy)	Award	$0	+238K		$0.00	238K	Dec 19, 2022	Common Stock	238K	$10.63	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.
F2	Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.